Morphic Holding Inc

NASDAQ:MORF   3:59:59 PM EDT
58.51
-0.73 (-1.23%)
Products

Morphic Reports New Data From Positive Phase 1 Study Of Morf-057, Oral Integrin Inhibitor Candidate For Ibd

Published: 07/09/2021 12:45 GMT
Morphic Holding Inc (MORF) - Morphic Reports New Data From Positive Phase 1 Study of Morf-057, Oral Integrin Inhibitor Candidate for Ibd.
Morphic Holding Inc - Morf-057 Well Tolerated Across All Phase 1 Cohorts.
Morphic Holding Inc - Dose-dependent Α4Β7 Receptor Occupancy (ro) Observed With Receptor Saturation at 100 Mg Dose.
Morphic Holding Inc - Biomarker Changes Including Lymphocyte Subset Migration and Ccr9 Transcript Levels Provide Early Proof of Biology.